Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Intensifying CEO Search; Gregory To Immediately Step Down

This article was originally published in The Pink Sheet Daily

Executive Summary

Gregory had planned to retire as CEO once a successor was found. King is facing federal investigations into its Medicaid rebate accounting practices and recently issued an earnings warning.

You may also be interested in...



Newcomer Graceway Acquires 3M’s American Pharmaceutical Business

Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.

Newcomer Graceway Acquires 3M’s American Pharmaceutical Business

Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.

Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol

The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel